Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan's Taisho Falters Under NHI Price Cuts; Eisai Squeezing Sales Out Of Aricept - Japanese Earnings Week

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Taisho Pharmaceutical Co. said it operated in a difficult business environment in 2010, attributing weak sales to National Health Insurance price cuts and decreased demand for cold remedies
Advertisement

Related Content

Taisho Buys Malaysia's Leading Domestic Pharma To Build Distribution Hub For APAC
Taisho Buys Malaysia's Leading Domestic Pharma To Build Distribution Hub For APAC
Approval Highs And Lows For Leading Japanese Pharma; Dogged By Competitors And Nagging Supply Issues
Eisai And Pfizer Begin Undertaking To Switch Appropriate Patients To High-dose Aricept
Taisho Acquires BMS Indonesia, OTC Assets; Price Tag Too High, Say Japanese Analysts
Taisho Acquires BMS Indonesia, OTC Assets; Price Tag Too High, Say Japanese Analysts
Advertisement
UsernamePublicRestriction

Register

SC077266

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel